P2RX7 and neoplasm: Further preclinical studies could explore whether P2X7 receptor agonism together with retinoic therapy, prior to chemotherapy, would modulate the tumor mass toward a more drug-responsive phenotype, avoiding the selection of less differentiated resistant cells.